Skip Nav Destination
Issues
1 April 2014
-
Cover Image
Cover Image
The cover shows a lymph node metastasis from a patient with prostate cancer. Lectin histochemistry with Helix pomatia agglutinin shows a decreasing surface presentation of terminal GalNAc- and GlcNAc-residues in lymph node metastasis. In conjunction with this finding, the authors demonstrate that metastatic prostate cancer cells can extravasate in the absence of selectins. For details, see the article by Lange and colleagues on page 1791 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
Special Report
AACR Celebrates 50 Years of Tobacco Research and Policy
Roy S. Herbst; Jennifer A. Hobin; Ellen R. Gritz; Writing Committee for the AACR Subcommittee on Tobacco and Cancer
Special Commentary
CCR Translations
Statistics in Clinical Cancer Research
CCR Drug Updates
Molecular Pathways
Review
Human Cancer Biology
Author Choice
Emergence of Constitutively Active Estrogen Receptor-α Mutations in Pretreated Advanced Estrogen Receptor–Positive Breast Cancer
Rinath Jeselsohn; Roman Yelensky; Gilles Buchwalter; Garrett Frampton; Funda Meric-Bernstam; Ana Maria Gonzalez-Angulo; Jaime Ferrer-Lozano; Jose A. Perez-Fidalgo; Massimo Cristofanilli; Henry Gómez; Carlos L. Arteaga; Jennifer Giltnane; Justin M. Balko; Maureen T. Cronin; Mirna Jarosz; James Sun; Matthew Hawryluk; Doron Lipson; Geoff Otto; Jeffrey S. Ross; Addie Dvir; Lior Soussan-Gutman; Ido Wolf; Tamar Rubinek; Lauren Gilmore; Stuart Schnitt; Steven E. Come; Lajos Pusztai; Philip Stephens; Myles Brown; Vincent A. Miller
Author Choice
T-cell Responses to Oncogenic Merkel Cell Polyomavirus Proteins Distinguish Patients with Merkel Cell Carcinoma from Healthy Donors
Rikke Lyngaa; Natasja Wulff Pedersen; David Schrama; Charlotte Albæk Thrue; Dafina Ibrani; Özcan Met; Per thor Straten; Paul Nghiem; Jürgen C. Becker; Sine Reker Hadrup
Author Choice
Primate-Specific miR-663 Functions as a Tumor Suppressor by Targeting PIK3CD and Predicts the Prognosis of Human Glioblastoma
Yu Shi; Cong Chen; Xia Zhang; Qing Liu; Jin-Ling Xu; Hua-Rong Zhang; Xiao-Hong Yao; Tao Jiang; Zhi-Cheng He; Yong Ren; Wei Cui; Chuan Xu; Ling Liu; You-Hong Cui; Shi-Zhu Yu; Yi-Fang Ping; Xiu-Wu Bian
Cancer Therapy: Preclinical
Author Choice
Combination of YM155, a Survivin Suppressant, with Bendamustine and Rituximab: A New Combination Therapy to Treat Relapsed/Refractory Diffuse Large B-cell Lymphoma
Naoki Kaneko; Keisuke Mitsuoka; Nobuaki Amino; Kentaro Yamanaka; Aya Kita; Masamichi Mori; Sosuke Miyoshi; Sadao Kuromitsu
A Short Treatment with Galactomannan GM-CT-01 Corrects the Functions of Freshly Isolated Human Tumor–Infiltrating Lymphocytes
Nathalie Demotte; René Bigirimana; Grégoire Wieërs; Vincent Stroobant; Jean-Luc Squifflet; Javier Carrasco; Kris Thielemans; Jean-François Baurain; Patrick Van Der Smissen; Pierre J. Courtoy; Pierre van der Bruggen
Author Choice
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic Cancers
Pablo D. Garcia; John L. Langowski; Yingyun Wang; Min Chen; Joseph Castillo; Christie Fanton; Marjorie Ison; Tatiana Zavorotinskaya; Yumin Dai; Jing Lu; Xiao-Hong Niu; Stephen Basham; Julie Chan; Jianjun Yu; Michael Doyle; Paul Feucht; Robert Warne; Jamie Narberes; Tiffany Tsang; Christine Fritsch; Audrey Kauffmann; Estelle Pfister; Peter Drueckes; Joerg Trappe; Christopher Wilson; Wooseok Han; Jiong Lan; Gisele Nishiguchi; Mika Lindvall; Cornelia Bellamacina; J. Alex Aycinena; Richard Zang; Jocelyn Holash; Matthew T. Burger
Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib
Jie Huang; Wei Hu; Justin Bottsford-Miller; Tao Liu; Hee Dong Han; Behrouz Zand; Sunila Pradeep; Ju-Won Roh; Duangmani Thanapprapasr; Heather J. Dalton; Chad V. Pecot; Rajesh Rupaimoole; Chunhua Lu; Bryan Fellman; Diana Urbauer; Yu Kang; Nicholas B. Jennings; Li Huang; Michael T. Deavers; Russell Broaddus; Robert L. Coleman; Anil K. Sood
Imaging, Diagnosis, Prognosis
Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
John Wrangle; Emi Ota Machida; Ludmila Danilova; Alicia Hulbert; Noreli Franco; Wei Zhang; Sabine C. Glöckner; Mathewos Tessema; Leander Van Neste; Hariharan Easwaran; Kornel E. Schuebel; Julien Licchesi; Craig M. Hooker; Nita Ahuja; Jun Amano; Steven A. Belinsky; Stephen B. Baylin; James G. Herman; Malcolm V. Brock
Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma
Markus Riester; Lillian Werner; Joaquim Bellmunt; Shamini Selvarajah; Elizabeth A. Guancial; Barbara A. Weir; Edward C. Stack; Rachel S. Park; Robert O'Brien; Fabio A.B. Schutz; Toni K. Choueiri; Sabina Signoretti; Josep Lloreta; Luigi Marchionni; Enrique Gallardo; Federico Rojo; Denise I. Garcia; Yvonne Chekaluk; David J. Kwiatkowski; Bernard H. Bochner; William C. Hahn; Azra H. Ligon; Justine A. Barletta; Massimo Loda; David M. Berman; Philip W. Kantoff; Franziska Michor; Jonathan E. Rosenberg
Circulating Oncometabolite 2-Hydroxyglutarate Is a Potential Surrogate Biomarker in Patients with Isocitrate Dehydrogenase-Mutant Intrahepatic Cholangiocarcinoma
Darrell R. Borger; Lipika Goyal; Thomas Yau; Ronnie T. Poon; Marek Ancukiewicz; Vikram Deshpande; David C. Christiani; Hannah M. Liebman; Hua Yang; Hyeryun Kim; Katharine Yen; Jason E. Faris; A. John Iafrate; Eunice L. Kwak; Jeffrey W. Clark; Jill N. Allen; Lawrence S. Blaszkowsky; Janet E. Murphy; Supriya K. Saha; Theodore S. Hong; Jennifer Y. Wo; Cristina R. Ferrone; Kenneth K. Tanabe; Nabeel Bardeesy; Kimberly S. Straley; Sam Agresta; David P. Schenkein; Leif W. Ellisen; David P. Ryan; Andrew X. Zhu
Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer
Maria-Gabriela Anitei; Guy Zeitoun; Bernhard Mlecnik; Florence Marliot; Nacilla Haicheur; Ana-Maria Todosi; Amos Kirilovsky; Christine Lagorce; Gabriela Bindea; Dan Ferariu; Mihai Danciu; Patrick Bruneval; Viorel Scripcariu; Jean-Marc Chevallier; Franck Zinzindohoué; Anne Berger; Jérôme Galon; Franck Pagès
Cancer Therapy: Clinical
A Phase I, Multicenter, Open-Label, First-in-Human, Dose-Escalation Study of the Oral Smoothened Inhibitor Sonidegib (LDE225) in Patients with Advanced Solid Tumors
Jordi Rodon; Hussein A. Tawbi; Anne L. Thomas; Ronald G. Stoller; Christian P. Turtschi; Jose Baselga; John Sarantopoulos; Devalingam Mahalingam; Yaping Shou; Melissa A. Moles; Lin Yang; Camille Granvil; Eunju Hurh; Kristine L. Rose; Dereck D. Amakye; Reinhard Dummer; Alain C. Mita
Author Choice
Topical Application of a Mucoadhesive Freeze-Dried Black Raspberry Gel Induces Clinical and Histologic Regression and Reduces Loss of Heterozygosity Events in Premalignant Oral Intraepithelial Lesions: Results from a Multicentered, Placebo-Controlled Clinical Trial
Susan R. Mallery; Meng Tong; Brian S. Shumway; Alice E. Curran; Peter E. Larsen; Gregory M. Ness; Kelly S. Kennedy; George H. Blakey; George M. Kushner; Aaron M. Vickers; Brian Han; Ping Pei; Gary D. Stoner
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer
Johann S. de Bono; Josep M. Piulats; Hardev S. Pandha; Daniel P. Petrylak; Fred Saad; Luis Miguel A. Aparicio; Shahneen K. Sandhu; Peter Fong; Silke Gillessen; Gary R. Hudes; Tao Wang; Judith Scranton; Michael N. Pollak
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura; Johanna Bendell; Guy Jerusalem; Shaun Su; Qinhua Ru; Stefan De Buck; David Mills; Sophie Ruquet; Ana Bosch; Ander Urruticoechea; Joseph T. Beck; Emmanuelle Di Tomaso; David W. Sternberg; Cristian Massacesi; Samit Hirawat; Luc Dirix; Jose Baselga
Predictive Biomarkers and Personalized Medicine
Author Choice
Prediction of Survival in Resected Non–Small Cell Lung Cancer Using a Protein Expression–Based Risk Model: Implications for Personalized Chemoprevention and Therapy
Kathryn A. Gold; Edward S. Kim; Diane D. Liu; Ping Yuan; Carmen Behrens; Luisa M. Solis; Humam Kadara; David C. Rice; Ignacio I. Wistuba; Stephen G. Swisher; Wayne L. Hofstetter; J. Jack Lee; Waun K. Hong
Author Choice
Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy
Martin H. Voss; A. Ari Hakimi; Can G. Pham; A. Rose Brannon; Ying-Bei Chen; Luis F. Cunha; Oguz Akin; Han Liu; Shugaku Takeda; Sasinya N. Scott; Nicholas D. Socci; Agnes Viale; Nikolaus Schultz; Chris Sander; Victor E. Reuter; Paul Russo; Emily H. Cheng; Robert J. Motzer; Michael F. Berger; James J. Hsieh
Author Choice
BRAF Inhibitor Resistance Mechanisms in Metastatic Melanoma: Spectrum and Clinical Impact
Helen Rizos; Alexander M. Menzies; Gulietta M. Pupo; Matteo S. Carlino; Carina Fung; Jessica Hyman; Lauren E. Haydu; Branka Mijatov; Therese M. Becker; Suzanah C. Boyd; Julie Howle; Robyn Saw; John F. Thompson; Richard F. Kefford; Richard A. Scolyer; Georgina V. Long
A Panel of Three Markers Hyper- and Hypomethylated in Urine Sediments Accurately Predicts Bladder Cancer Recurrence
Sheng-Fang Su; André Luís de Castro Abreu; Yoshitomo Chihara; Yvonne Tsai; Claudia Andreu-Vieyra; Siamak Daneshmand; Eila C. Skinner; Peter A. Jones; Kimberly D. Siegmund; Gangning Liang
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa; Miguel Angel Molina; Ana Drozdowskyj; Ana Giménez-Capitán; Jordi Bertran-Alamillo; Niki Karachaliou; Radj Gervais; Bartomeu Massuti; Jia Wei; Teresa Moran; Margarita Majem; Enriqueta Felip; Enric Carcereny; Rosario Garcia-Campelo; Santiago Viteri; Miquel Taron; Mayumi Ono; Petros Giannikopoulos; Trever Bivona; Rafael Rosell
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds